Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.
Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.
The funds will support the progression of MindRank’s pipeline, which is heavily dominated by obesity indications.
The Ara Parseghian Medical Research Fund will provide financial backing for the multi-year research effort.
Polpharma Biologics will retain full responsibility for developing and manufacturing the biosimilar candidate.
The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.
